Neurogene to present NGN-401 Rett syndrome gene therapy data at ESGCT congress
NGNE•Neurogene will present NGN-401 Rett syndrome gene therapy data at the ESGCT annual congress in Hamburg, Germany, from Oct. 27-30, 2026. The presentations include Phase 1/2 gene expression timing and early treatment-response observations, plus preclinical gene regulation comparisons.
1. Congress presentations
Neurogene will present NGN-401 data at the ESGCT annual congress in Hamburg, Germany, from Oct. 27-30, 2026. An Oct. 29 presentation will examine gene expression timing alongside early treatment-response observations from the Phase 1/2 trial. Oct. 28 presentations will cover preclinical comparisons of gene regulation approaches, including the company’s EXACT technology.
